Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma

被引：0
|
作者：
Lokhorst, Henk M.
Plesner, Torben
Gimsing, Peter
Nahi, Hareth
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Laubach, Jacob
Lisby, Steen
Basse, Linda
Richardson, Paul Gerard Guy
机构：
[1] UMC Utrecht, Utrecht, Netherlands
[2] Vejle Hosp, Vejle, Denmark
[3] Copenhagen Univ Hosp, Copenhagen, Denmark
[4] Karolinska Univ, Sjukhuset Huddinge, Huddinge, Sweden
[5] Rigshosp, DK-2100 Copenhagen, Denmark
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA
[7] Genmab AS, Copenhagen, Denmark
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8512
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A PHASE IB DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND IV BORTEZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    San Miguel, J.
    Sezer, O.
    Siegel, D.
    Guenther, A.
    Blade, J.
    Prosser, I.
    Hazell, K.
    Bengoudifa, R.
    Klebsattel, M.
    Bourquelot, P.
    Cavo, M.
    Goebeler, M.
    Niederweiser, D.
    Milder, M.
    Boccadoro, M.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 155 - 155
  • [22] ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
    Shah, Jatin J.
    Zonder, Jeffrey
    Cohen, Adam
    Orlowski, Robert Z.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna
    Kaufman, Jonathan L.
    Harvey, R. Donald
    Walker, Duncan
    Litwiler, Kevin
    Karan, Sharon
    Hilder, Brandi
    Ptaszynski, Ann Marie
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 809 - 810
  • [23] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [24] A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Wendtner, C. M.
    Mahadevan, D.
    Coutre, S.
    Hillmen, P.
    Stilgenbauer, S.
    Frankfurt, O.
    Bloor, A.
    Bosch, F.
    Furman, R.
    Uharek, L.
    Kimby, E.
    Gobbi, M.
    Dreisback, L.
    Hurd, D.
    Sekeres, M.
    Gribben, J.
    Shah, S.
    Parseval, L. Moutouh-de
    Chanan-Khan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 371 - 372
  • [25] Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 438 - 445
  • [26] Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Yee, Andrew
    Laubach, Jacob
    Nooka, Ajay
    O'Donnell, Elizabeth
    Harrington, Cynthia
    Agyemang, Emerentia
    Burke, Jill
    Gammon, Marilyn
    Lively, Kathleen
    Packer, Lisette
    Bishop, James
    Bernstein, Zachary
    Lyons, Rebecca
    Wright, Alexandra
    McVey, Cailin
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S58 - S59
  • [27] Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Nooka, Ajay K.
    O'Donnell, Elizabeth K.
    Weller, Edie A.
    Couture, Nicole R.
    Wallace, Ellen E.
    Burke, Jill N.
    Harrington, Cynthia C.
    Puccio-Pick, Marie
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [28] DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY EFFICACY AND PHARMACOKINETICS DATA FROM A DOSE-ESCALATION PHASE I/II STUDY
    Lokhorst, H.
    Gimsing, P.
    Nahi, H.
    Richardson, P.
    Plesner, T.
    Lisby, S.
    HAEMATOLOGICA, 2012, 97 : 473 - 473
  • [29] A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
    Bueno, Orlando
    Slimp, Rachel
    Jacobson, Michelle
    Pesko, John Carl
    Li, Hong
    Ross, Jeremy A.
    Freise, Kevin
    Maciag, Paulo Cesar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex
    Kambhampati, Swetha
    Wong, Sandy W.
    Martin, Thomas, III
    Wolf, Jeffrey L.
    Choudhry, Priya
    Karlon, William
    Wiita, Arun P.
    Shah, Nina
    BLOOD, 2020, 136
12345